Navigation

Rheumatoid arthritis - tocilizumab

Tocilizumab for the treatment of rheumatoid arthritis

Status: History
Expected date of issue: August 2010
Referral date: July 2008
Process: STA
Topic area:
 

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: Joanne Fielding & Christian Griffiths
Communications manager: Tonya Gillis
Project manager: Lori Farrar
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 06 February 2009
1st appraisal committee meeting: 14 May 2009
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers / Sponsors

  • Roche Products (tocilizumab)

Patient / Carer Groups

  • Arthritis & Musculoskeletal Alliance (ARMA)
  • Arthritis Care
  • National Rheumatoid Arthritis Society

Professional Groups

  • British Health Professionals in Rheumatology
  • British Society for Rheumatology
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians

Others

  • Department of Health
  • Welsh Assembly Government

General

  • Department of Health, Social Services and Public Safety for Northern Ireland
  • NHS Quality Improvement Scotland

Possible comparator manufacturer(s)

  • Abbott Laboratories (adalimumab)
  • AstraZeneca UK (chloroquine)
  • GlaxoSmith Kline (azathioprine)
  • Novartis (ciclosporin)
  • Pfizer (methotrexate, sulfasalazine)
  • Roche Products (rituximab)
  • Sanofi Aventis (hydroxychloroquine, leflunomide, sodium aurothiomalate)
  • Schering-Plough (infliximab)
  • Wyeth Pharmaceuticals (etanercept)

Relevant research Groups

  • None

Evidence Review Group

  • West Midlands Health Technology Assessment Collaboration
  • National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme)

Associated Guideline Groups

  • None

Associated Public Health Groups

  • None

Top


 

Project history

Date Update
1 June 2009 The manufacturer of the drug have informed us that the date on which this drug will be launched in the UK has not been finalised and consequently the final price has not been formally announced. We therefore cannot release the decision agreed by the Committee and the evidence documentation related to the appraisal at this time.
25 September 2009 The appraisal has been reactivated because the price has now been formally registered. The price will shortly be made publicly available and  therefore the appraisal will recommence in line with the normal STA process. We will issuing a further update within the next week.
21 April 2010 Two appraisal committee meetings on this appraisal topic took place on 11 November 2009 and 10 February 2010. The next discussion on this appraisal topic is delayed until May 12 2010 Committee C meeting, (from the original schedule of 13 April 2010).  The reason for the delay is to allow sufficient time to consider the manufacturer (Roche) ACD response.
Top


 

Key documents

This page was last updated: 25 August 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.